Gain of function p53 mutant R273H confers distinct methylation profiles and consequent YAP/TAZ signaling mediated activation of partial or full EMT states to colon tumours

p53 功能获得性突变体 R273H 赋予结肠肿瘤不同的甲基化谱,并由此导致 YAP/TAZ 信号介导的部分或完全 EMT 状态激活。

阅读:2

Abstract

BACKGROUND: Mutations in tumour suppressor p53 are frequently implied in aggressive progression and metastasis in colorectal cancer. But the distinct phenotypes exhibited by site-specific mutations of p53 are not well elucidated. Here, we investigate the epigenetic and transcriptional impact of three major p53 hotspot mutations (R175H, R273H and R282W), through DNA methylation changes and single cell transcriptomics. RESULTS: We observed that the p53 R273H mutation is associated with a partial epithelial-mesenchymal transition (pEMT) and increased metastatic progression. Analysis of DNA methylation patterns revealed a distinct epigenetic landscape in R273H-mutant tumours, with hypomethylated regions correlating with enhanced transcriptional activation of YAP/TAZ target genes thus promoting pEMT and EMT-like phenotype in CRC tumours. In vitro ChIP-seq experiments in colorectal cancer cells expressing the R273H mutant p53 (HT29) showed enrichment of mutant p53 at the promoters of YAP/TAZ target genes suggesting EMT/pEMT like states with R273H mutation. Further, simulations from a gene regulatory network incorporating the interactions of p53R273H with EMT regulators explain how this mutation shapes the phenotypic landscape accessible to cancer cells. Our analysis of single-cell transcriptomes of colorectal tumours reveals R273H-linked enrichment of partial and mesenchymal EMT phenotypes across tumour subpopulations in CRC. CONCLUSIONS: We identified a distinct epigenetic signature associated with the p53 R273H mutation, characterised by hypomethylation of YAP/TAZ signalling genes that drives partial EMT and aggressive tumour behaviour. These findings highlight the importance of mutation-specific epigenetic regulation in shaping colorectal cancer progression and the need for developing therapeutic strategies tailored to p53 mutation status.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。